Letters were sent to the CEOs of AbbVie (ABBV), Boehringer Ingelheim, Bristol Myers Squibb (BMY), Novartis (NVS), Gilead Sciences (GILD), EMD Serono, Pfizer (PFE), Novo Nordisk (NVO), AstraZeneca (AZN), Amgen (AMGN), Genentech (RHHBY), Johnson & Johnson (JNJ), GSK (GSK), Merck (MRK), Regeneron (REGN), Sanofi (SNY) and Eli Lilly (LLY), according to posts made by President Trump to his Truth Social account.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Upadacitinib Study Completion: Market Implications and Insights
- AbbVie and Genmab’s Phase 3 Trial of Epcoritamab: A Potential Game-Changer for DLBCL Treatment
- AbbVie’s Promising New Study on ABBV-453 for Multiple Myeloma
- AbbVie Advances in Psoriatic Arthritis Treatment: A New Phase 2 Study Update
- AbbVie’s Phase 3 Study on Pediatric Atopic Dermatitis: A Potential Game-Changer?